Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFLY Butterfly Network	$1.53 +9.7%	$1.78	$0.90 ▼ $4.98	$382.65M	2.45	3.62 million shs	4.32 million shs
DCTH Delcath Systems	$11.12 +6.8%	$11.87	$7.85 ▼ $18.23	$388.99M	0.82	826,901 shs	771,937 shs
OBIO Orchestra BioMed	$2.55 +2.4%	$2.91	$2.37 ▼ $7.04	$98.54M	0.62	451,225 shs	188,395 shs
RXST RxSight	$9.28 +6.3%	$9.72	$6.32 ▼ $58.23	$379.70M	1.16	1.13 million shs	1.35 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFLY Butterfly Network	0.00%	+6.64%	-26.86%	-30.05%	+63.28%
DCTH Delcath Systems	0.00%	+7.34%	-2.46%	-30.97%	+39.52%
OBIO Orchestra BioMed	0.00%	-0.78%	-20.81%	-6.25%	-60.03%
RXST RxSight	0.00%	+10.08%	+16.88%	-40.82%	-82.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BFLY Butterfly Network	2.9546 of 5 stars	3.4	3.0	2.6	2.5	0.6
DCTH Delcath Systems	2.785 of 5 stars	3.5	2.0	2.6	2.5	0.6
OBIO Orchestra BioMed	3.1441 of 5 stars	3.5	5.0	2.2	2.5	0.0
RXST RxSight	0.9842 of 5 stars	2.0	1.0	2.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFLY Butterfly Network	2.75	Moderate Buy	$3.00	96.72% Upside
DCTH Delcath Systems	3.00	Buy	$24.50	120.32% Upside
OBIO Orchestra BioMed	3.00	Buy	$14.00	449.02% Upside
RXST RxSight	1.91	Reduce	$10.00	7.76% Upside

Current Analyst Ratings Breakdown

Latest OBIO, BFLY, DCTH, and RXST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	OBIO Orchestra BioMed	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
8/13/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/8/2025	RXST RxSight	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
8/8/2025	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$9.00 ➝ $8.00
8/8/2025	RXST RxSight	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $11.00
8/7/2025	DCTH Delcath Systems	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$29.00 ➝ $31.00
8/7/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/4/2025	BFLY Butterfly Network	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Positive ➝ Positive	$2.00
8/1/2025	BFLY Butterfly Network	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/15/2025	RXST RxSight	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$20.00 ➝ $9.00
7/10/2025	RXST RxSight	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$24.00 ➝ $9.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFLY Butterfly Network	$82.06M	4.68	N/A	N/A	$0.92 per share	1.66
DCTH Delcath Systems	$37.21M	10.45	N/A	N/A	$3.00 per share	3.71
OBIO Orchestra BioMed	$2.64M	37.32	N/A	N/A	$0.01 per share	255.00
RXST RxSight	$139.93M	2.71	N/A	N/A	$6.79 per share	1.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFLY Butterfly Network	-$72.49M	-$0.28	N/A	N/A	N/A	-71.79%	-30.53%	-21.80%	11/7/2025 (Estimated)
DCTH Delcath Systems	-$26.39M	$0.05	222.40	N/A	N/A	3.18%	6.91%	5.80%	N/A
OBIO Orchestra BioMed	-$61.02M	-$1.83	N/A	N/A	N/A	-2,367.49%	-289.42%	-110.04%	11/11/2025 (Estimated)
RXST RxSight	-$27.45M	-$0.80	N/A	N/A	N/A	-21.93%	-11.56%	-10.31%	11/6/2025 (Estimated)

Latest OBIO, BFLY, DCTH, and RXST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	OBIO Orchestra BioMed	-$0.51	-$0.50	+$0.01	-$0.50	$0.78 million	$0.84 million
8/7/2025	Guidance Update	RXST RxSight	-$0.04	-$0.08	-$0.04	-$0.29	$39.78 million	$33.64 million
8/6/2025	Q2 2025	DCTH Delcath Systems	$0.02	$0.07	+$0.05	$0.07	$22.84 million	$24.16 million
8/1/2025	Q2 2025	BFLY Butterfly Network	-$0.07	-$0.06	+$0.01	-$0.06	$23.91 million	$23.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFLY Butterfly Network	N/A	N/A	N/A	N/A	N/A
DCTH Delcath Systems	N/A	N/A	N/A	N/A	N/A
OBIO Orchestra BioMed	N/A	N/A	N/A	N/A	N/A
RXST RxSight	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFLY Butterfly Network	N/A	5.68	4.14
DCTH Delcath Systems	N/A	10.88	9.87
OBIO Orchestra BioMed	48.76	2.10	2.09
RXST RxSight	N/A	13.93	12.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFLY Butterfly Network	37.85%
DCTH Delcath Systems	61.12%
OBIO Orchestra BioMed	53.20%
RXST RxSight	78.78%

Insider Ownership

Company	Insider Ownership
BFLY Butterfly Network	25.18%
DCTH Delcath Systems	17.40%
OBIO Orchestra BioMed	8.10%
RXST RxSight	9.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFLY Butterfly Network	460	251.74 million	188.35 million	Optionable
DCTH Delcath Systems	60	34.98 million	28.89 million	Optionable
OBIO Orchestra BioMed	4	38.64 million	35.51 million	Not Optionable
RXST RxSight	220	40.92 million	37.00 million	Optionable

OBIO, BFLY, DCTH, and RXST Headlines

Recent News About These Companies

ROSEN, NATIONAL TRIAL COUNSEL, Encourages RxSight, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RXST

August 24 at 9:10 AM | markets.businessinsider.com

RxSight, Inc. $RXST Shares Bought by Quantbot Technologies LP

August 24 at 5:16 AM | marketbeat.com

RXST CLASS REMINDER: Suffer Losses on Your RxSight, Inc. Investment? Contact BFA Law before the September 22 Court Deadline (NASDAQ:RXST)

August 23 at 7:08 AM | globenewswire.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages RxSight, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RXST

August 22 at 5:56 PM | globenewswire.com

Lost Money on RxSight, Inc.(RXST)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

August 22 at 4:43 PM | globenewswire.com

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight

August 22 at 10:25 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming Deadlines - RXST

August 22 at 10:00 AM | prnewswire.com

RxSight, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RXST

August 22 at 8:45 AM | prnewswire.com

Credit Agricole S A Has $19.85 Million Position in RxSight, Inc. $RXST

August 22 at 5:48 AM | marketbeat.com

Algert Global LLC Has $3.51 Million Stock Position in RxSight, Inc. $RXST

August 22 at 4:44 AM | marketbeat.com

RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit

August 21 at 9:26 PM | prnewswire.com

Lost Money on RxSight, Inc.(RXST)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm

August 21 at 3:23 PM | globenewswire.com

Deadline Alert: RxSight, Inc. (RXST) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

August 21 at 1:58 PM | globenewswire.com

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight

August 21 at 11:25 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming Deadlines - RXST

August 21 at 10:36 AM | globenewswire.com

Class Action Filed Against RxSight, Inc. (RXST) - September 22, 2025 Deadline to Join - Contact The Gross Law Firm

August 21 at 8:45 AM | prnewswire.com

RXST DEADLINE NOTICE: RxSight, Inc. Investors are Notified of the September 22 Class Action Deadline -- Contact BFA Law if You Suffered Losses (NASDAQ:RXST)

August 21 at 8:18 AM | globenewswire.com

Shareholders who lost money on their RxSight, Inc. (NASDAQ: RXST) Investment Should Contact Wolf Haldenstein Immediately as the Lead Plaintiff Deadline is September 22nd

August 21 at 7:05 AM | prnewswire.com

RXST Stockholders with Large Losses Should Contact Robbins LLP for Information About the RxSight, Inc. Class Action

August 20, 2025 | prnewswire.com

RXST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 20, 2025 | globenewswire.com

RXST SECURITIES: RxSight, Inc. Shareholders that Lost Money may have been Affected by Fraud -- ...

August 19, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO, BFLY, DCTH, and RXST Company Descriptions

Butterfly Network NYSE:BFLY

$1.52 +0.14 (+9.71%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$1.52 0.00 (0.00%)

As of 08/22/2025 07:57 PM Eastern

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

Delcath Systems NASDAQ:DCTH

$11.12 +0.71 (+6.82%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$11.06 -0.06 (-0.55%)

As of 08/22/2025 07:42 PM Eastern

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Orchestra BioMed NASDAQ:OBIO

$2.55 +0.06 (+2.41%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.58 +0.03 (+0.98%)

As of 08/22/2025 07:47 PM Eastern

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

RxSight NASDAQ:RXST

$9.28 +0.55 (+6.30%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.24 -0.04 (-0.43%)

As of 08/22/2025 07:46 PM Eastern

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time